Phase III Clinical Trial to Evaluate the Protective Efficacy, Immunogenicity, and Safety of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in People Aged 6 Weeks to 13 Years
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Norovirus vaccine quadrivalent-Anhui Zhifei Longcom Biologic Pharmacy (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms Pichia Pastoris
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
- 23 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2024 New trial record